Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MC1431 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer

NCT02860000 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02860000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02860000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MC1431 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2017
Completion date
February 14, 2025
Enrollment
96 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor status, her2/neu negative, invasive breast carcinoma, postmenopausal, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer